.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Harvard Business School
Fuji
Boehringer Ingelheim
Argus Health
Dow
Novartis
Moodys
UBS
Farmers Insurance

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075138

« Back to Dashboard
NDA 075138 describes VERAPAMIL HYDROCHLORIDE, which is a drug marketed by Glenmark Generics, Mylan, Luitpold, Actavis Elizabeth, Pliva, Sandoz, Watson Labs, Exela Pharma Scs Llc, Sun Pharm Inds Inc, Ivax Sub Teva Pharms, Marsam Pharms Llc, Hospira, Warner Chilcott, Abraxis Pharm, Intl Medication, Par Pharm, Cadila Pharms Ltd, Apotex Corp, Heritage Pharms Inc, Mutual Pharm, Bedford, Sun Pharm Inds, Solopak, and Smith And Nephew, and is included in fifty-four NDAs. It is available from thirty-six suppliers. Additional details are available on the VERAPAMIL HYDROCHLORIDE profile page.

The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

Summary for NDA: 075138

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 075138

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 075138 ANDA Mylan Pharmaceuticals Inc. 0378-6320 0378-6320-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-6320-01)
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 075138 ANDA Mylan Pharmaceuticals Inc. 0378-6380 0378-6380-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-6380-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength120MG
Approval Date:Apr 20, 1999TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength180MG
Approval Date:Apr 20, 1999TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength240MG
Approval Date:Apr 20, 1999TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Citi
UBS
Johnson and Johnson
Queensland Health
Deloitte
McKinsey
AstraZeneca
Farmers Insurance
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot